Join us in-person for the 2025 DTRF "Together We Will" Weekend in Chicago from Sept. 12-13! - Register Today

The Desmoid Tumor Research Foundation

August 2019

Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis

Author Information

Pannier D(1), Cordoba A(2), Ryckewaert T(1), Robin YM(3), Penel N(4).

(1)Dept of Medical Oncology, Centre Oscar Lambert, Lille, France. (2)Dept of Radiation Oncology, Centre Oscar Lambret, Lille, France. (3)Dept of Bio-Pathology, Centre Oscar Lambret, Lille, France. (4)Medical School, Lille Univ, Lille, France.

Publication

Crit Rev Oncol Hematol

Summary

We review the role of hormonal therapy in the management of different conjunctive tumors. Progestin and aromatase inhibitors seem active in low-grade endometrial stromal sarcoma, but larger case-series are needed. The use of aromatase inhibitor in estrogen-receptor-positive uterine leiomyosarcoma requires further clinical investigation. There is no evidence supporting the use of hormonal therapy in desmoid-type fibromatosis.

View Abstract